Amneal Q1 revenue $558M (+12% YoY); adj. EBITDA $116M (+16%); reaffirms FY guidance

Amneal Pharmaceuticals, Inc.

2023-Q1 EPS reported -$0.05 revenue$557,540,000

Net revenue $558M, up 12% YoY; driven by generics, specialty (Rytary, Unithroid), and AvKARE expansion.
Net loss $7M ($0.05 loss per share) vs $2M loss last year; adjusted EPS $0.12 flat YoY.
Adjusted EBITDA $116M, up 16% YoY; company reaffirms full-year 2023 guidance.
Fourth and largest injectables facility successfully inspected; IPX203 PDUFA date June 30.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Amneal Pharmaceuticals, Inc. reported first quarter ended March 31, 2023 results: revenue $558 million, net income $7 million, EPS $0.05. Guidance reaffirmed.

Period: first quarter ended March 31, 2023
Revenue: $558 million
Net income: $7 million
EPS: $0.05
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Q1 2023 Net Revenue of $558 million; GAAP Net Loss of $7 million; Diluted Loss per Share of $0.05 ‒ ‒ Adjusted EBITDA (1) of $116 million; Adjusted Diluted EPS (1) of $0.12 ‒ ‒ Affirming 2023 Full Year Guidance

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Amneal Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001723128-23-000017

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.